Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2019 | NIVOREN GETUG-AFU 26: Updates and implications

Laurence Albiges • 1 Oct 2019
ESMO 2019
Genitourinary Cancer Kidney Cancer Antibodies Nivolumab

Laurence Albiges, MD, PhD, Gustave Roussy Institute, Villejuif, France, speaking on the NIVOREN GETUG-AFU 26 study: the real-world implications of nivolumab in metastatic renal cell carcinoma patients. This interview was recorded at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

More from Laurence Albiges

2:48
LITESPARK-005: Belzutifan versus everolimus in ccRCC
Laurence Albiges • 21 Oct 2023
4:21
Biomarker development in RCC and UC
Laurence Albiges • 23 Sep 2021
2:24
Current and emerging treatment strategies for patients with mccRCC
Laurence Albiges • 23 Sep 2021
1:50
BIONIKK: the first trial study in mccRCC
Laurence Albiges • 18 Sep 2020

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals